The European Medicines Agency has agreed to review the application of  GlaxoSmithKline‘s belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company announced in a press release. Specifically, the marketing authorization application is for people with relapsed or refractory disease who received prior treatment with an …
STRO-001, Sutro Biopharma’s investigational therapy for multiple myeloma, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). “There is a growing need for new treatment options for patients with multiple myeloma,” Bill Newell, Sutro’s CEO, said in a news release. “This orphan drug…
The U.S. Food and Drug Administration has approved a combination of once-weekly Kyprolis (carfilzomib), developed by Amgen, and dexamethasone for the treatment of multiple myeloma patients who failed prior therapies. “In the fight against multiple myeloma, we are committed to continued evidence generation and innovation to serve patients. Kyprolis…
Leukogene Therapeutics, a startup company from the Medical University of South Carolina (MUSC), has been awarded a $2 million Small Business Technology Transfer (STTR) grant to continue developing a new compound for treatment-resistant multiple myeloma. The treatment prototype has shown promise in preclinical studies of treatment-resistant…
Get regular updates to your inbox.